Doctor Won't Prescribe GLP-1 for Weight Loss? Your Alternative Options
Your doctor refused to prescribe Wegovy, Ozempic, or a GLP-1 for weight loss. This guide explains the most common reasons for refusal, which are legitimate, and what your options are — including how to get a GLP-1 prescription online for $99/month.
Written by Trimi Medical Team. Medically reviewed by Trimi Medical Review Board. This article is for informational purposes only.
More on Access & Supply
You meet the BMI criteria. You have done your research. You asked your doctor about semaglutide or tirzepatide — and they said no. Or they said "let's try other things first." Or they said they don't prescribe those medications.
Physician refusal to prescribe GLP-1 medications for weight loss is more common than most patients expect. Understanding why it happens — and distinguishing between legitimate clinical refusals and administrative hesitancy — is the first step to knowing what your options actually are.
Why Doctors Refuse to Prescribe GLP-1 for Weight Loss
GLP-1 refusals from primary care providers fall into several categories. Identifying which category applies to your situation determines your next move.
Category 1: Legitimate clinical contraindication
Personal or family history of medullary thyroid carcinoma (MTC), Multiple Endocrine Neoplasia type 2 (MEN2), active pancreatitis, or known hypersensitivity to semaglutide are real contraindications. If your doctor declined specifically because of one of these, their concern is clinically valid. A telehealth provider will make the same determination.
What to do: Respect this refusal and discuss it with your provider in detail.
Category 2: Insurance and prior authorization burden
Many primary care providers find GLP-1 prior authorization extremely time-consuming — documentation requirements, phone calls with insurance medical directors, and high denial rates make it unattractive to initiate. Some practices have developed policies around not initiating GLP-1 PAs. This is an administrative refusal, not a clinical one.
What to do: Ask about referral to an obesity medicine specialist, or access through a telehealth provider with no PA required.
Category 3: Clinical familiarity gaps
GLP-1 medications for weight loss are relatively new in clinical practice. Some PCPs are not yet comfortable prescribing them — they may not be familiar with the STEP trial data, the dose titration protocol, or the side-effect management practices. This leads to hesitancy that presents as refusal.
What to do: Request a referral to an obesity medicine specialist, or use a telehealth provider who specializes specifically in GLP-1 prescribing.
Category 4: Philosophical stance on obesity treatment
Some providers have a personal belief that obesity should be managed through lifestyle modification rather than medication, or that pharmaceutical approaches are premature before exhausting behavioral options. This reflects the physician's values rather than current obesity medicine guidelines or evidence.
What to do: Seek a second opinion. The American Academy of Obesity Medicine endorses pharmacological treatment as an evidence-based option alongside lifestyle modification.
Category 5: Misunderstanding of FDA indications
Some providers conflate Ozempic (FDA-approved for type 2 diabetes) with Wegovy (FDA-approved for weight management in adults without diabetes). They may incorrectly tell patients that GLP-1s are only for diabetics. Wegovy's weight-management indication explicitly covers patients without diabetes at BMI ≥ 30 or ≥ 27 with a comorbidity.
What to do: Clarify whether they are aware of Wegovy's specific weight-management indication, or seek a provider who is.
How to Have a Productive Conversation with Your Doctor
If your doctor has been hesitant rather than explicitly refusing, a more prepared conversation may change the outcome. Here is how to approach it:
Questions to ask your provider
- Can you explain specifically why you are not comfortable prescribing this for me?
- Are there clinical contraindications specific to my case, or is this a general practice preference?
- Would you be willing to refer me to an obesity medicine specialist?
- If my concern is about the insurance PA process — would you prescribe if I handled the documentation preparation, or if I used a cash-pay option?
- Are you aware of Wegovy's specific FDA approval for weight management in patients without diabetes?
Your Four Main Options After a Refusal
1Request a Referral to an Obesity Medicine Specialist
Obesity medicine is a recognized medical specialty. Board-certified obesity medicine specialists are trained specifically in pharmacological and comprehensive management of obesity. They are far more likely to be comfortable prescribing GLP-1 medications and managing the associated documentation.
Limitation: Obesity medicine specialists typically have wait lists of 3–6 months in most metropolitan areas, and may not be available in rural regions.
2Seek a Second Opinion From Another PCP
Physicians are individuals with individual clinical judgment and prescribing comfort. The fact that one PCP declined does not mean all will. A second opinion from a different primary care provider — particularly one with more familiarity with obesity medicine guidelines — may result in a prescription.
Limitation: Still requires insurance navigation and PA for brand-name, which may result in delays and further barriers.
3Access GLP-1 Through a Telehealth Provider — Starting at $99/Month
Telehealth providers like Trimi are independent clinical practices staffed by board-certified providers who specialize in GLP-1 prescribing. They conduct an independent evaluation of your health history and — if you meet the clinical criteria — prescribe compounded semaglutide or tirzepatide without requiring any referral or prior authorization.
- Independent evaluation — not bound by your primary care provider's decision
- No insurance required — $99/month flat for compounded semaglutide
- Provider review within 24 hours of completing online assessment
- Medication delivered within 5–10 business days
- Ongoing provider access for dose management throughout treatment
This is the fastest and most accessible path for patients who meet the clinical criteria and have been denied through traditional prescribers. Full details: how GLP-1 online prescriptions work in 2026.
4Community Health Center (FQHC)
Federally Qualified Health Centers serve uninsured and underinsured patients and often have providers with more flexibility in prescribing obesity medications. They use sliding-scale fees for visits, and may access GLP-1 medications at reduced cost through the 340B program. Call local FQHCs to ask about availability.
What Telehealth Providers Can and Cannot Override
It is important to be clear about what seeking a telehealth GLP-1 prescription means — and what it does not mean.
A telehealth provider CAN:
- Conduct an independent clinical evaluation of your health history
- Prescribe if you meet the clinical criteria, regardless of your primary care provider's preference
- Prescribe compounded semaglutide or tirzepatide as a cash-pay program — no insurance required
- Manage your ongoing GLP-1 treatment including dose adjustments and side-effect support
A telehealth provider CANNOT:
- Override a legitimate clinical contraindication — if you have MEN2 or active pancreatitis, both your PCP and a telehealth provider will decline
- Prescribe without a thorough health evaluation — any legitimate provider requires full medical history disclosure
- Replace your primary care relationship for your other health conditions
- Manage complex conditions (uncontrolled diabetes, active cardiovascular disease) without coordination with your primary care team
Telling Your Regular Doctor You Started GLP-1 Through Telehealth
Starting semaglutide through a telehealth provider does not require your primary care physician's permission — but your PCP should know about it. Semaglutide affects other medications, particularly diabetes drugs and insulin. If your PCP manages your blood pressure, cholesterol, or diabetes medications, they need an updated medication list to make safe prescribing decisions for your other conditions.
How to approach the conversation: "I have started a GLP-1 medication through a telehealth provider. I wanted you to know so you can update my medication list. The medication is semaglutide [dose], prescribed by [provider name]. I would like to continue seeing you for my other care."
Most providers, even those who declined to prescribe themselves, will continue to manage your other health concerns. A minority may decline to continue the relationship — in which case finding a new primary care provider is appropriate.
Evidence Your Doctor May Not Have Reviewed
If you want to have an informed conversation with your hesitant provider before seeking alternatives, here is the key evidence they may not have fully reviewed:
Wegovy FDA approval (2021)
FDA approved semaglutide 2.4mg (Wegovy) for chronic weight management in adults with initial BMI ≥ 30 or ≥ 27 with a weight-related comorbidity — specifically for patients without type 2 diabetes, as well as those with it.
STEP 1 trial: 14.9% weight loss at 68 weeks
Wilding JPH et al., NEJM 2021. The landmark trial establishing semaglutide's clinical efficacy — the largest effect size of any anti-obesity medication trialed to that point. This is the evidence base for the FDA approval.
SELECT cardiovascular outcomes trial (2023)
Lincoff AM et al., NEJM 2023. Semaglutide 2.4mg reduced major adverse cardiovascular events by 20% in adults with overweight or obesity without diabetes — supporting broader use beyond diabetes management.
AACE and ACOM guidelines
The American Association of Clinical Endocrinologists and the American Board of Obesity Medicine both endorse pharmacological treatment — including GLP-1 receptor agonists — as first-line adjunctive therapy to lifestyle for patients meeting BMI criteria.
Realistic Timeline After a Doctor Refusal
| Path | Estimated time to first dose | Monthly cost |
|---|---|---|
| Telehealth provider (Trimi) | 7–10 business days | $99 (semaglutide) / $125 (tirzepatide) |
| Second PCP opinion (with PA) | 4–10 weeks (appointment + PA) | Copay + brand-name drug cost |
| Obesity medicine specialist | 3–6 months (wait list) | Copay + brand-name drug cost |
| FQHC community health center | Varies by facility | Sliding scale + potentially 340B pricing |
Getting Started With Trimi After a Provider Refusal
The Trimi evaluation is entirely independent of your existing provider relationship. Here is what to expect:
- 1Complete the online health assessment — include your full medical history, current medications, and the reason your previous provider declined if you know it
- 2Be honest about contraindications — if you have a family history of MTC or MEN2, disclose it. A legitimate provider will decline appropriately
- 3Provider reviews within 24 hours and makes an independent prescribing decision
- 4If approved, medication ships to your door within 5–10 business days at $99/month for semaglutide
- 5Inform your regular doctor that you are starting semaglutide through a telehealth provider
For more information on how the process works: GLP-1 without a doctor appointment in 2026, weight loss medication with no wait list, and why compounded semaglutide costs $99/month.
Frequently Asked Questions
Why do doctors sometimes refuse to prescribe GLP-1 medications for weight loss?
There are several common reasons: concern about off-label use (some providers are hesitant to prescribe Ozempic for weight loss given its diabetes indication), insurance and prior authorization complexity (many PCPs find the PA process burdensome and avoid initiating it), familiarity gaps with newer obesity medicine guidelines, concerns about side effects or long-term safety, or a general philosophical stance that obesity should be managed through lifestyle rather than medication. Some refusals are based on legitimate clinical concerns; others reflect prescriber hesitancy rather than patient-specific factors.
What should I do if my doctor refuses to prescribe a GLP-1?
First, ask your doctor specifically why they are declining — a clinical reason (contraindication) is different from administrative hesitancy or personal philosophy. If the reason is clinical, you should understand it. If it is administrative or philosophically based, your options include: requesting a referral to an obesity medicine specialist, seeking a second opinion from another PCP, or accessing GLP-1 medications through a telehealth provider like Trimi that specializes in GLP-1 prescribing.
Can I get a GLP-1 prescription from a telehealth provider if my doctor refused?
Yes, with an important caveat: telehealth providers are independent licensed clinicians who make their own prescribing decisions based on your health profile. If your doctor refused due to a legitimate medical contraindication (MEN2 history, active pancreatitis, etc.), a telehealth provider will also decline for the same reason. If your doctor refused for administrative reasons, prescriber hesitancy, or insurance issues, a telehealth provider may prescribe if you meet the clinical criteria. The evaluation is independent and based on your health information.
Is it ethical to get a GLP-1 prescription from a telehealth provider after my doctor refused?
It is entirely appropriate to seek a second medical opinion or to use a different provider for a different service. Doctors have individual clinical judgment and individual prescribing practices. Telehealth providers who specialize in obesity medicine are not overriding your doctor — they are providing an independent clinical evaluation. As long as you disclose your complete medical history honestly (including your doctor's concerns if known), you are acting appropriately.
My doctor says GLP-1 is only for people with diabetes. Is that accurate?
No, that is not accurate as of 2026. Wegovy (semaglutide 2.4mg) received FDA approval for chronic weight management in adults with BMI ≥ 30 or BMI ≥ 27 with a weight-related comorbidity in 2021 — this approval is specifically for weight management regardless of diabetes status. Ozempic is FDA-approved for type 2 diabetes specifically, but semaglutide's weight-loss indication through Wegovy is not diabetes-dependent. Your doctor may be conflating the two products.
What if I meet the BMI criteria but my doctor still won't prescribe?
Meeting clinical criteria does not obligate any individual physician to prescribe. Physicians have the right to decline prescribing based on their clinical judgment. Your options are: request a specialist referral, seek a second opinion, or access the medication through a telehealth provider who evaluates you independently. At $99/month for compounded semaglutide through Trimi, you can access treatment without depending on your current provider's willingness to prescribe.
Should I tell my regular doctor if I start semaglutide through a telehealth provider?
Yes, it is important to inform your regular doctor that you are taking semaglutide. It affects other medications — particularly insulin and diabetes drugs, which may need dose reduction to avoid hypoglycemia. Your regular doctor manages your other health conditions and should have a complete medication list. Trimi can provide documentation of your prescription for your records.
Related Reading
Sources & References
- STEP 1 trial: Wilding JPH et al. Once-Weekly Semaglutide. NEJM 2021;384:989–1002.
- SELECT trial: Lincoff AM et al. Semaglutide and Cardiovascular Outcomes. NEJM 2023;389:2221–2232.
- FDA prescribing information for Wegovy (semaglutide injection 2.4mg).
- HHS telehealth prescribing regulations.
- Obesity Medicine Association. Obesity Algorithm — clinical guidelines.
- FDA guidance on pharmaceutical compounding.
Medical Disclaimer: This content is for informational purposes only. Telehealth providers make independent clinical decisions — accessing a telehealth evaluation does not guarantee a prescription. Always disclose your complete medical history accurately. Inform your primary care provider of any new medications you start. Trimi provides compounded GLP-1 medications through licensed providers — this article reflects our perspective as a provider in this space.